Hot Flash Management: Update of the Evidence for Patients With Cancer

Marcelle Kaplan, RN, MS, AOCN®, CBCN®, and Suzanne Mahon, RN, DNSc, AOCN®, APNG

Hot flashes are a distressing symptom frequently experienced by survivors of breast cancer or prostate cancer who are receiving estrogen or androgen-deprivation therapies. The frequency and intensity of hot flashes can lead to diminished quality of life and decreased adherence with prescribed antineoplastic therapies. This evidence-based review synthesizes and updates the findings of the highest quality evidence-based studies of interventions to manage hot flashes resulting from cancer therapies in patients with breast or prostate cancer since the initial Putting Evidence Into Practice review of hot flashes in 2011. Recent studies involving a variety of pharmacologic and nonpharmacologic interventions were evaluated and, as reported in 2011, the drugs gabapentin and venlafaxine were the only therapies rated as likely to be effective. In addition, a strong placebo effect was noted in several studies that included a placebo intervention and should be considered when reviewing interventions for hot flashes.

Marcelle Kaplan, RN, MS, AOCN®, CBCN®, is a self-employed breast oncology nurse consultant in Merick, NY, and Suzanne Mahon, RN, DNSc, AOCN®, APNG, is a professor in the Department of Internal Medicine in the School of Medicine at Saint Louis University in Missouri. The authors take full responsibility for the content of the article. The authors did not receive honoraria for this work. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or editorial staff. Descriptions of products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society. Kaplan can be reached at marcelle.kaplan@gmail.com, with copy to editor at CJONEditor@ons.org. (Submitted April 2014. Revision submitted June 2014. Accepted for publication June 12, 2014.)

Key words: hot flashes; breast cancer; prostate cancer; symptom management

Digital Object Identifier: 10.1188/14.CJON.S3.59-67

Hot flashes are often a lasting and distressing side effect of antineoplastic treatment, particularly for women with breast cancer and men with prostate cancer. Hot flashes have been reported in 65%–80% of breast cancer survivors (Kontos, Agbaje, Rymer, & Fentiman, 2010; Mann et al., 2012) and as many as 80% of men with prostate cancer treated with androgen-deprivation therapy (ADT) (Frisk, 2010). A hot flash has been defined as “a subjective sensation of heat that is associated with objective signs of cutaneous vasodilation and a subsequent drop in core temperature” (Boekhout, Beijnen, & Schellens, 2006, p. 642). Hot flashes generally involve the face and chest and are characterized by their transient and unpredictable nature (Jones, Kohli, & Loprinzi, 2012). The vasomotor symptoms that characterize hot flashes (e.g., feelings of intense heat, profuse sweating, flushing) have a negative effect on sleep, energy, sexuality, and overall quality of life (Kadakia, Loprinzi, & Barton, 2012).

Hot flashes are reported to be significantly more frequent and severe in women treated for breast cancer than in women undergoing natural menopause (Carpenter, 2005; Kadakia et al., 2012). Hot flashes are believed to be precipitated by the abrupt suppression of ovarian function caused by chemotherapy-induced premature menopause and/or the use of estrogen withdrawal therapies, including tamoxifen and aromatase inhibitors (Baber, Hickey, & Kwik, 2005; Howell et al., 2005; Morrow, Mattair, & Hortobagyi, 2011). Tamoxifen has been shown to produce more frequent and severe hot flashes than the aromatase inhibitors anastrozole and letrozole (Howell et al., 2005; Morrow et al., 2011). Men with advanced prostate cancer who receive ADT via surgical or chemical castration also experience distressing hot flashes that may persist for at least eight years following treatment (Frisk, 2010).

The exact physiologic mechanisms of hot flashes are unknown, and what is known comes mainly from studies with menopausal women (Shanafelt, Barton, Adjei, & Loprinzi, 2002). Core body temperature is regulated centrally in the hypothalamus and is maintained within a narrow physiologic set range called the thermoneutral zone. Elevations of core temperature above the set range stimulate the hypothalamus to activate such heat-dissipating mechanisms as profuse sweating and cutaneous vasodilation, manifested as hot flashes (Dalal & Zhukovsky, 2006; Morrow et al., 2011). Plasma sex hormones (estrogen in women, gonadal hormones in men) are involved in...
regulating the hypothalamic thermoregulatory center through negative feedback mechanisms involving the neurotransmitters serotonin and norepinephrine (Shanafelt et al., 2002). The abrupt withdrawal of sex hormones, which occurs with estrogen therapy or ADT, leads to dysfunction of the thermoregulatory center in the hypothalamus whereby even small, transitory elevations in the core temperature trigger the heat-loss mechanisms characteristic of hot flashes (Boekhout et al., 2006; Kouriefs, Georgiou, & Ravi, 2002; Shanafelt et al., 2002).

Subjective measures of hot flashes include assessing the frequency, severity, intensity, distress, and interference with daily activities (Carpenter, Wu, Burns, & Yu, 2012). Data collected from retrospective self-reported hot flash diaries that have been validated in women with breast cancer and men with prostate cancer (the Loprinzi and Sloan Self-Report Diary) (Sloan et al., 2001), as well as in women with breast cancer (the Hot Flash-Related Daily Interference Scale) (Carpenter, 2001), are deemed sufficient for clinical practice (Hanisch et al., 2009; Loprinzi & Barton, 2009).

For an overview of the methods used in creating the Putting Evidence Into Practice (PEP®) resources, see Johnson (2014). The current article updates and synthesizes the evidence for interventions to manage hot flashes in women with breast cancer and men with prostate cancer since those presented by Kaplan et al. (2011). Search methods are available at www.ons.org/content/hot-flashes-search-strategy. Sources of evidence are divided into pharmacologic and nonpharmacologic interventions.

Pharmacologic Interventions

Likely to Be Effective

Gabapentin: Several randomized, controlled clinical trials demonstrated the efficacy of gabapentin in reducing hot flashes in women with breast cancer, as described in Kaplan et al. (2011) and in a systematic review by Rada et al. (2010). In addition, a randomized crossover study of gabapentin and venlafaxine in women with breast cancer (N = 38) revealed that both agents decreased hot flashes. Gabapentin was associated with more dizziness (p = 0.005) and increased appetite (p < 0.001) (Bordeleau et al., 2010). A self-report study of 117 men with prostate cancer who received gabapentin 600 mg per day showed moderately decreased hot flash scores without substantial toxicities (Moraska et al., 2010).

Venlafaxine: Several randomized, controlled trials have demonstrated the efficacy of venlafaxine, a selective serotonin reuptake inhibitor (SSRI) antidepressant, in reducing hot flashes. A randomized crossover study of 38 women with breast cancer compared gabapentin and venlafaxine, and both agents were found to decrease hot flashes. Venlafaxine was associated with loss of appetite (p = 0.003), nausea (p = 0.02), and constipation (p = 0.05), but fewer negative mood changes (p = 0.01) than gabapentin (Bordeleau et al., 2010). A 12-week, double-blind trial comparing clonidine, venlafaxine, and placebo in 80 women with a history of breast cancer found venlafaxine and clonidine were slightly more effective than placebo in reducing hot flash symptoms. Of note, all study groups showed significant reduction in symptoms at 12 weeks, including the placebo group, which reported a 29% decrease in hot flashes (Boekhout et al., 2011). Venlafaxine was not found to be superior to cyproterone acetate and medroxyprogesterone acetate in a double-blind randomized study of men experiencing significant hot flushes during androgen-suppression therapy (N = 109). However, no placebo control group was included (Irani, Salomon, Oba, Bouchard, & Mottet, 2010).

Effectiveness Not Established

Clonidine: In prior randomized trials, clonidine demonstrated a moderate reduction in tamoxifen-induced hot flashes in women with breast cancer (Buiks et al., 2009), in association with a significant placebo effect (Pandya et al., 2000), and was shown to be less effective than venlafaxine (Loibl et al., 2007). A similar placebo-controlled trial in men treated with orchietomy for prostate cancer found no significant benefit for clonidine (Loprinzi, Goldberg, et al., 1994). In a systematic review, Rada et al. (2010) reported that clonidine provided benefit in reducing hot flashes in women with breast cancer. A randomized, double-blind, placebo-controlled, 12-week study of 80 women with a history of breast cancer compared clonidine, venlafaxine, and placebo. Hot flash scores were found to be significantly lower in the clonidine group versus placebo (p = 0.03), were not significantly different for venlafaxine versus placebo (p = 0.07), and were equal in the clonidine and venlafaxine groups (Boekhout et al., 2011). However, Loprinzi, Barton, and Qin (2011) cited methodologic issues related to the study, including an inadequate sample size per study arm, an unbalanced randomization scheme (2:2:1), and an uneven dropout rate among treatment arms.

Progestin therapies: Mixed results were reported in studies examining the efficacy of megestrol and medroxyprogesterone in reducing hot flashes in men with prostate cancer and women with breast cancer (Bertelli et al., 2002; Frisk, 2010; Goodwin et al., 2008; Loprinzi, Michalak, et al., 1994). A systematic literature review of hot flash interventions for men treated for prostate cancer found that some hormone agents were able to decrease hot flashes by at least 75% but produced severe side effects. Cyproterone acetate was associated with fatigue, weight gain, depressed mood, gynecomastia, and hot flashes. Megestrol produced weight gain, edema, and nausea and increased the prostatic-specific antigen in one patient, raising concerns about promoting prostate cancer (Frisk, 2010). All studies were too limited to evaluate safety and long-term risks of treatment. Irani et al. (2010) conducted a 12-week double-blind study of three drugs to manage hot flashes in men receiving ADT for prostate cancer: venlafaxine 75 mg per day (n = 102), medroxyprogesterone acetate 20 mg per day (n = 108), or cyproterone acetate 100 mg per day (n = 101). No comparator placebo control arm was included. All three drugs were found to reduce hot flashes in men, but cyproterone acetate and medroxyprogesterone were most effective (Irani et al., 2010). However, cyproterone acetate is used to treat prostate cancer and could interfere with ADT (Jones et al., 2012). In general, hormone therapies are not recommended for patients with prostate or breast cancer because of concerns about promoting tumor growth (Rada et al., 2010).

Stellate ganglion block: A stellate ganglion block is an injection of local anesthetic into the sympathetic nerve tissue in the anterior neck. A small study (N = 15) that investigated the effectiveness of stellate ganglion block in women with breast cancer and hot flashes found a significant decrease in weekly
hot flash episodes during a 12-week period (Lipov et al., 2008). In a prospective single-arm trial, 34 women with breast cancer who were resistant to other therapies were treated with a stel-
late ganglion block. Although hot flashes were reduced initially,
they gradually returned over time (Haest et al., 2012).

Zolpidem: In one study, 53 women with breast cancer were
asked whether they were currently using an SSRI or a serotonin-
norepinephrine reuptake inhibitor (SNRI) to treat hot flash-
es. Those taking an SSRI or SNRI were instructed to continue
on the medication. Nonusers were started on venlafaxine (an
SSRI) at 75 mg per day. All participants were then randomized
to receive daily zolpidem 10 mg or placebo for five weeks.
Although no change was seen in the number of hot flashes,
zolpidem appeared to improve the perception of nighttime hot
flashes, perhaps by allowing the patient to sleep through the
hot flash (Joffe et al., 2010).

Other Interventions
Bupropion: In a randomized, double-blind, crossover, placebo-
controlled pilot study of bupropion 150 mg in breast cancer
survivors (N = 55), participants reported a larger reduction in
hot flashes with placebo and a preference for placebo (Nuñez
et al., 2013).

Citalopram: One randomized, placebo-controlled, double-
blind trial evaluated three oral dosages of citalopram (10 mg,
20 mg, and 30 mg per day) versus placebo for six weeks in 254
postmenopausal women experiencing hot flashes. Ninety-one
participants had a history of breast cancer, and 69 were receiving
concurrent estrogen-deprivation therapy. Hot flash scores
decreased from baseline with all dose levels of citalopram com-
pared with placebo (p ≤ 0.002). No significant response to doses
of more than 10 mg per day was noted (Barton et al., 2010).

Magnesium: In a small observational study, 25 women with
breast cancer experiencing hot flashes completed treatment
with magnesium 400 mg per day for four weeks, escalating to
800 mg per day if needed. Reductions in weekly hot flash scores
(frequency times severity) ranged from more than 50% to more
than 25% (Park, Parker, Boardman, Morris, & Smith, 2011).

Miscellaneous agents: Other pharmacologic agents investigated
in small studies that produced mixed results include transder-
mal estrogen patches in men (Gerber, Zagaja, Ray, & Rukstalis,
2011).

Studies show two drugs may help to decrease hot flashes.
Many studies have been done to see what types of
treatment can help relieve hot flashes in patients
with breast cancer or prostate cancer. Results of
this research have shown that only two treatments
are likely to be useful. They are both drugs.
- Gabapentin (Neurontin®), a drug used to treat
  epilepsy and some types of pain
- Venlafaxine (Effexor®), a type of antidepressant

Other treatment methods that do not have
enough research to recommend use
Other treatment methods that have been studied
for relieving hot flashes in patients with breast
cancer or prostate cancer include the use of:
- Many different types of drugs
- Herbal or dietary supplements

Hot flashes may be an unpleasant side effect of
cancer treatment, particularly for women with
breast cancer and men with prostate cancer. Pa-
tients report periods of intense heat, sweating, and
reddenning of the skin on the face and chest. Hot
flashes may occur often or only a few times each
day or night. Patients may wake up several times
during the night and feel tired during the day.

Studies show two drugs may help to decrease hot flashes.

Patient Education: Hot Flashes Associated With Treatment for Breast or Prostate Cancer

- Acupuncture
- Hypnosis
- Relaxation therapy.

None of these treatments can be recommended for
use at this time. More research is needed to see if
any of these methods can help relieve hot flashes
over a long period of time.

Some tips to help stay cool and decrease hot flashes
These tips are not based on the results of research
studies.
- Learn what triggers your hot flashes, such as
  hot beverages and spicy foods. Avoid them.
- Limit coffee drinking.
- Do not drink alcohol.
- Dress in layers of clothing that can be removed.
- Keep the room cool for sleeping.
- Sleep on cotton sheets.
- Wear cotton or quick-drying sleepwear.

Note. Full Oncology Nursing Society Putting Evidence Into
Practice information for this topic and description of the
categories of evidence are located at www.ons.org/practice-
resources/pep/hot-flashes. Users should refer to this resource
for full dosages, references, and other essential information
about the evidence.
Several randomized trials of acupuncture in women with breast cancer and men with prostate cancer that demonstrated a decrease in hot flashes were identified. However, methodologic issues included sample sizes of fewer than 75 participants in all studies combined and limited follow-up that did not exceed six months in any study (Deng et al., 2007; de Valois, Young, Robinson, McCourt, & Maher, 2010; Filshie, Bolton, Browne, & Ashley, 2005; Frisk et al., 2008; Frisk, Källström, Wall, Fredriksson, & Hammar, 2012; Hervik & Mjøland, 2009; Liljegren et al., 2012; Nedstrand, Wijma, Wyon, & Hammar, 2005; Otte, Carpenter, Zhong, & Johnstone, 2011; Walker et al., 2010). A prospective single-arm trial of 14 men with prostate cancer found a short-term decrease in hot flash intensity and frequency (Ashamalla, Jiang, Guirguis, Peluso, & Ashamalla, 2011). Similar findings were reported by Beer et al. (2010) in a study of 22 men with prostate cancer. A prospective, double-blind, randomized study in women with “troublesome” hot flashes related to breast cancer therapies tested the effect of real acupuncture (n = 31) against sham acupuncture (n = 29) and no treatment (n = 34). The researchers reported that significant relief was achieved after the second real acupuncture treatment compared to the sham acupuncture and no-treatment groups (p < 0.05) that lasted for at least 12 weeks. However, some women in all groups concurrently received a variety of other hot flash therapies, including clonidine and/or venlafaxine, mirtazapine with clonidine, and hormone replacement (Bokmard & Flyger, 2012).

In a systematic review of 41 randomized clinical trials, the efficacy of acupuncture for symptoms other than chemotherapy-induced nausea and vomiting could not be determined because of the high risk of bias among the studies (Garcia et al., 2015). A systematic review of 16 studies that compared acupuncture versus sham acupuncture did not provide sufficient evidence to determine whether acupuncture is an effective treatment for vasomotor symptoms. Debate exists about whether sham acupuncture is a placebo intervention or whether it possesses an active effect related to peripheral sensory stimulation (Dodin et al., 2013).

Nonpharmacologic Interventions

Effectiveness Not Established

Acupuncture: Several randomized trials of acupuncture in women with breast cancer and men with prostate cancer that demonstrated a decrease in hot flashes were identified. However, methodologic issues included sample sizes of fewer than 75 participants in all studies combined and limited follow-up that did not exceed six months in any study (Deng et al., 2007; de Valois, Young, Robinson, McCourt, & Maher, 2010; Filshie, Bolton, Browne, & Ashley, 2005; Frisk et al., 2008; Frisk, Källström, Wall, Fredriksson, & Hammar, 2012; Hervik & Mjøland, 2009; Liljegren et al., 2012; Nedstrand, Wijma, Wyon, & Hammar, 2005; Otte, Carpenter, Zhong, & Johnstone, 2011; Walker et al., 2010). A prospective single-arm trial of 14 men with prostate cancer found a short-term decrease in hot flash intensity and frequency (Ashamalla, Jiang, Guirguis, Peluso, & Ashamalla, 2011). Similar findings were reported by Beer et al. (2010) in a study of 22 men with prostate cancer. A prospective, double-blind, randomized study in women with “troublesome” hot flashes related to breast cancer therapies tested the effect of real acupuncture (n = 31) against sham acupuncture (n = 29) and no treatment (n = 34). The researchers reported that significant relief was achieved after the second real acupuncture treatment compared to the sham acupuncture and no-treatment groups (p < 0.05) that lasted for at least 12 weeks. However, some women in all groups concurrently received a variety of other hot flash therapies, including clonidine and/or venlafaxine, mirtazapine with clonidine, and hormone replacement (Bokmard & Flyger, 2012).

In a systematic review of 41 randomized clinical trials, the efficacy of acupuncture for symptoms other than chemotherapy-induced nausea and vomiting could not be determined because of the high risk of bias among the studies (Garcia et al., 2015). A systematic review of 16 studies that compared acupuncture versus sham acupuncture did not provide sufficient evidence to determine whether acupuncture is an effective treatment for vasomotor symptoms. Debate exists about whether sham acupuncture is a placebo intervention or whether it possesses an active effect related to peripheral sensory stimulation (Dodin et al., 2013).

Cognitive-behavioral interventions: In a randomized, controlled trial, Ganz et al. (2000) studied the impact of comprehensive menopausal symptom assessment in 42 breast cancer survivors and found no change in the number of hot flashes. Using similar methodology, an exploratory trial of 17 women with breast cancer showed a decrease in the number of hot flashes (Hunter, Coventry, Hamed, Fentiman, & Grunfeld, 2009). In a study by Mann et al. (2012), 96 symptomatic women seen in a breast cancer clinic were enrolled in a randomized trial in which individualized “usual care” by breast care nurses was compared to usual care plus group cognitive-behavioral therapy (CBT) intervention. Group CBT incorporated group discussions, handouts, and weekly homework with audio instructions for daily relaxation and paced breathing exercises at home. Little difference in hot flash frequency and night sweats was found between the two groups at weeks 9 and 26 (Mann et al., 2012). Members of both groups received individualized attention and may have benefited from the placebo effect. A study of 422...
women with breast cancer randomized to CBT, physical exercise, CBT and physical exercise, or a control group found that CBT resulted in a significant decrease in the perceived burden of hot flashes and night sweats using the problem-rating portion of the Hot Flush Rating Scale (p < 0.001, effect size = 0.39–0.56) (Duijts et al., 2012).

Other interventions: Several studies evaluating the effectiveness of black cohosh have provided conflicting evidence (Hernández Muñoz & Pluchino, 2003; Jacobson et al., 2001; Pockaj et al., 2006; Rostock et al., 2011). Other intervention strategies with limited research that demonstrated some decrease in hot flashes include peer counseling (Schover et al., 2006), relaxation therapy (Fenlon, Corner, & Haviland, 2008; Rada et al., 2010), yoga (Carson, Carson, Porter, Keefe, & Seewaldt, 2009), hypnosis (Elkins et al., 2008; Elkins, Marcus, Stearns, & Rajab, 2007; Younus, Simpson, Collins, & Wang, 2003), and Salvia officinalis (i.e., a medicinal herb more commonly known as sage) (Vandecasteele et al., 2012).

Effectiveness Unlikely

Homeopathy: The homeopathy approach to treating hot flashes usually involves a consultation with a homeopathic practitioner who prescribes an individualized homeopathic remedy. The ingredients and doses of the homeopathic remedies reported in several studies were unclear or lacking (Clover & Ratsey, 2002; Jacobs, Herman, Heron, Olsen, & Vaughters, 2005; Thompson & Reilly, 2003) making it impossible to replicate the intervention in clinical practice or truly evaluate the effectiveness of the intervention (Rada et al., 2010).

Soy supplements: Depending on the study, soy supplements were provided in the form of capsules, tablets, powder, or beverage (MacGregor, Canney, Patterson, McDonald, & Paul, 2005; Nikander, Metsa-Heikkilä, Ylikorkala, & Tiitinen, 2004; Quella et al., 2000; Sharma et al., 2009; Van Patten et al., 2002). A 12-week placebo-controlled study randomized 120 androgen-deprived men with prostate cancer and hot flashes to venlafaxine alone, venlafaxine plus soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, soy alone, or placebo. Results indicated that neither venlafaxine nor soy, so...
This article provides an overview and evaluation of the interventions that have been studied to manage hot flashes in cancer survivors, particularly individuals with breast or prostate cancer. Additional randomized clinical trials with long-term follow-up for safety and efficacy are needed for all interventions. Nurses should remember the contributions of the placebo effect when reviewing the results of published studies about hot flash management.

The authors gratefully acknowledge the contributions of the following Oncology Nursing Society staff: Margaret Irwin, RN, PhD, Lee Ann Johnson, MSN, RN, Kerri A. Moriarty, MLS, and Mark Vrabel, MLS, AHIP, ELS; as well as members of the Putting Evidence Into Practice hot flash team: Elizabeth Abernathy, RN, MSN, APRN, AOCN®, Dale Grimmer, RN, MS, AOCN®, CCRC, and Paz Fernandez-Ortega, RN.

References


